87 related articles for article (PubMed ID: 1830096)
1. Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma.
Negrier S; Michon J; Floret D; Bouffet E; Gentet JC; Philip I; Cochat P; Stamm D; Costil J; Gaspard M
J Clin Oncol; 1991 Aug; 9(8):1363-70. PubMed ID: 1830096
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-2 in neuroblastoma: clinical perspectives based on biological studies.
Rueda F; Martí F; Pardo N; Badell I; Peiró M; Bertran E; Villén E; García J; Cubells J
Cancer Biother Radiopharm; 1996 Oct; 11(5):303-8. PubMed ID: 10851509
[TBL] [Abstract][Full Text] [Related]
3. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
4. [Adoptive immunotherapy with interleukin 2 in oncology].
Favrot M; Bouffet E; Négrier S; Combaret V; Philip I; Philip T
Bull Cancer; 1990; 77(9):925-31. PubMed ID: 2224165
[TBL] [Abstract][Full Text] [Related]
5. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
6. High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study.
Pardo N; Martí F; Fraga G; Illa J; Badell I; Peiró M; Bertran E; García J; Rueda F; Cubells J
Med Pediatr Oncol; 1996 Dec; 27(6):534-9. PubMed ID: 8888813
[TBL] [Abstract][Full Text] [Related]
7. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia.
Benyunes MC; Massumoto C; York A; Higuchi CM; Buckner CD; Thompson JA; Petersen FB; Fefer A
Bone Marrow Transplant; 1993 Aug; 12(2):159-63. PubMed ID: 8401364
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A
Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
11. A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 cases.
Favrot M; Floret D; Michon J; Negrier S; Bouffet E; Coze C; Gaspard M; Cochat P; Thiesse P; Andreu G
Cancer Treat Rev; 1989 Jun; 16 Suppl A():129-42. PubMed ID: 2670209
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.
Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH; Sznol M; Mier J; Sparano J; Fisher RI; Weiss G
J Clin Oncol; 1991 Apr; 9(4):641-8. PubMed ID: 2066760
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication.
Foreman NK; Rill DR; Coustan-Smith E; Douglass EC; Brenner MK
Br J Cancer; 1993 May; 67(5):933-8. PubMed ID: 8494726
[TBL] [Abstract][Full Text] [Related]
15. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
[TBL] [Abstract][Full Text] [Related]
16. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
Osenga KL; Hank JA; Albertini MR; Gan J; Sternberg AG; Eickhoff J; Seeger RC; Matthay KK; Reynolds CP; Twist C; Krailo M; Adamson PC; Reisfeld RA; Gillies SD; Sondel PM;
Clin Cancer Res; 2006 Mar; 12(6):1750-9. PubMed ID: 16551859
[TBL] [Abstract][Full Text] [Related]
17. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial.
Dillman RO; Oldham RK; Tauer KW; Orr DW; Barth NM; Blumenschein G; Arnold J; Birch R; West WH
J Clin Oncol; 1991 Jul; 9(7):1233-40. PubMed ID: 2045864
[TBL] [Abstract][Full Text] [Related]
18. Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation.
Favrot MC; Floret D; Negrier S; Cochat P; Bouffet E; Zhou DC; Franks CR; Bijman T; Brunat-Mentigny M; Philip I
Bone Marrow Transplant; 1989 Sep; 4(5):499-503. PubMed ID: 2790327
[TBL] [Abstract][Full Text] [Related]
19. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
Lee K; O'Donnell RW; Cockett AT
J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
